FDA 批准 Attruby™ 用于治疗患有 ATTR-CM 的成人，将主要心脏事件减少 42%。 FDA approves Attruby™ for treating adults with ATTR-CM, reducing major heart events by 42%.

FDA 已批准 Attruby™ 用于治疗患有转甲状腺素蛋白心脏淀粉样变性 （ATTR-CM） 的成人患者，从而减少心血管死亡和住院治疗。 The FDA has approved Attruby™ for treating adults with transthyretin cardiac amyloidosis (ATTR-CM), reducing cardiovascular death and hospitalization. 作为第一种几乎完全稳定转甲状腺素蛋白的药物，Attruby 在 3 期研究中显示出显着益处，与安慰剂相比，主要心血管事件减少了 42%。 As the first drug to stabilize transthyretin proteins near completely, Attruby showed significant benefits in a Phase 3 study, reducing major cardiovascular events by 42% compared to a placebo. 该药物的批准还触发了根据特许权使用费协议向 BridgeBio Pharma 支付 5 亿美元的款项。 Approval of this drug also triggers a $500 million payment to BridgeBio Pharma under a royalty agreement.